TrialThe Lancet. Infectious diseases2021

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Yanjun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.